Novartis cholesterol setback tests hopes for emerging heart disease drugs

Live updates

1. 5d ago

   Novartis Cholesterol Drug Trial Failure Tests Heart Medicine Hopes

   Novartis shares fell 10% following the failure of its Lp(a) drug pelacarsen in a Phase 3 trial designed to lower cardiovascular risk. The negative outcome triggered a broader selloff affecting Ionis and Amgen, driven by investor concerns regarding an entire class of emerging heart medicines. Cardiologists previously anticipated the drug would act as a major defense against heart attacks. This unexpected trial result marks part of a severe week for Novartis, which has endured three trial failures and headed toward its worst trading day on record.

   Why it matters

   Pharmaceutical companies have poured billions of dollars into developing these treatments as the next frontier in cardiovascular care. The recent clinical setbacks have shocked medical professionals and cast doubt on the commercial and medical viability of similar competing products currently under development across the industry.

   What is confirmed

   • Novartis announced that its drug failed in a large clinical trial after heart doctors widely expected it to become a major weapon against heart attacks.
   • Novartis shares dropped 10% after its Lp(a) drug pelacarsen failed a Phase 3 trial to lower cardiovascular risk.
   • The trial failure triggered a selloff for Novartis, Ionis, and Amgen due to investor fear regarding emerging heart medicines.

   Still unconfirmed

   • Investors fear the failure reflects a broader issue with an emerging class of heart medicines.
   • The setback is part of a difficult week for Novartis, which has faced three drug trial failures, leading the company toward its worst day on record.

   What to watch next

   • Further data releases or safety disclosures from the other pipeline drugs developed by Novartis, Ionis, and Amgen.
   • Cardiology community responses and peer-reviewed data publications regarding the specific reasons for the pelacarsen trial failure.
   Sources used for this update (5)

   1. pharma.economictimes.indiatimes.com — News From Reuters
   2. medicalxpress.com — Cardiologists expected this new drug to prevent heart attacks—so why did it fail?
   3. www.marketscreener.com — HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating
   4. www.statnews.com — Why two promising heart drugs flopped and what’s next
   5. www.marketscreener.com — Eli Lilly Looks to Channel GLP-1 Revenue Into Women's Health
   confidence 90%
2. 7d ago

   Novartis Heart Drug Pelacarsen Fails Phase 3 Trial

   Novartis shares dropped 10% after its Lp(a) drug, pelacarsen, failed a Phase 3 trial to lower cardiovascular risk. The result has triggered a selloff for Novartis, Ionis, and Amgen, as investors fear the failure reflects a broader issue with an emerging class of heart medicines. This setback is part of a difficult week for Novartis, which has faced three drug trial failures, leading the company toward its worst day on record. The outcome has shocked cardiologists and raised questions about the viability of similar competing products currently in development.

   Why it matters

   Lp(a) drugs target a specific type of cholesterol to reduce heart disease risk. This failure impacts a competitive sector where multiple pharmaceutical companies are racing to develop similar therapies. The market reaction indicates that pelacarsen was viewed as a bellwether for the entire drug class.

   What is confirmed

   • The Novartis drug pelacarsen failed a Phase 3 trial to lower cardiovascular risk.
   • Novartis shares fell 10% following the trial results.
   • The failure of the Novartis drug led to after-hours stock drops for Ionis and Amgen.
   • Novartis has experienced three drug trial setbacks recently.

   Still unconfirmed

   • The pelacarsen failure fuels fears of similar outcomes for several competing products in development.
   • Novartis is heading for its worst day on record.

   What to watch next

   • Analysis of the specific trial data to determine why pelacarsen failed
   • Updates on competing Lp(a) drug trials from Amgen or other rivals
   • Official statements from Ionis regarding their partnership or pipeline impact
   Sources used for this update (12)

   1. The New York Times — Another Heart Drug Fails, Shocking Cardiologists
   2. Yahoo Finance — NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?
   3. fiercebiotech.com — Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
   4. BioPharma Dive — Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
   5. Reuters — Novartis cholesterol setback tests hopes for emerging heart disease drugs
   6. WSJ — Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial
   7. FirstWord Pharma — Novartis' pelacarsen fails critical cardiovascular test
   8. CNBC — Pharma major Novartis plummets 10%, heading for worst day on record after three drug trial setbacks
   9. Reuters — Novartis shares sink on second pipeline setback this week
   10. WSJ — Novartis’s Latest Trial Setback Sinks Stock
   11. www.marketscreener.com — Cloverleaf Bio announced that it has received $33 million in funding from a group of investors
   12. www.marketscreener.com — Amgen caught in the crossfire of Novartis' failure
   confidence 90%